

Endologix Investor Relations Department 2 Musick Irvine, CA 92618 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: ELGX	
Last Trade:	4.99
Trade Time:	4:00 PM ET Jul 27, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	4.21 - 14.41
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

Addressing a signi... (more)

Stock Performance



Press Releases [View all]

Jul 12, 2017

Endologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017

Jul 10, 2017

Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

Jun 3, 2017

Endologix Presents Positive Two-Year
Clinical Data from the Nellix® EVAS
FORWARD IDE Trial

May 31, 2017

Endologix Reports Positive Clinical Data from the Ovation LUCY Study

May 17, 2017

Endologix Provides an Update on the Nellix®
Endovascular Aneurysm Sealing System
U.S. Regulatory Status

Upcoming Events [View all]

Aug 2, 2017 4:30 PM ET
Endologix 2017 Second Quarter Financial
Results Conference Call

Aug 9, 2017 2:30 PM ET
Canaccord Genuity 37th Annual Growth
Conference

Financials [View all]

First Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

May 1, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)